September 22, 2016

September 23, 2016

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–

IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible) (IMPL.PA) (OTCQX:IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announces its financial results for the 1^st half of the year to June 30, 2016, as approved by the Board at its meeting of September 20, 2016.

Revenue: further ramping up of Jazz in the United States and France

Over the 1^st half of 2016, the Group recorded revenue of €4.094 thousand, up 24% compared with the 1^st half of 2015, notably due to a further increase in Spine activity (+38% compared with H1 2015). This growth momentum was a direct result of Implanet’s growth in the United States and France, markets in which Implanet markets its Jazz technological platform directly and where sales increased by 101% and 40% respectively. Close to 800 surgical interventions were carried out using the Jazz technological platform in the 1^st half of 2016, taking the total number of patients treated via this technology to more than 2,800 since its launch in 2013 (with more than 15,000 implants in total).

The substantial acceleration in the number of surgical operations carried out reflects the growing adoption of Jazz technology by surgeons around the world (111 surgeons as of June 30, 2016), notably due to the excellent clinical results obtained by Jazz in adults and adolescents and the growing use of Jazz technology on the degenerative bone disorder segment, the largest market segment.

Knee activity recorded a 12% increase in sales to €2.1 million over the first six months of the year. As anticipated, this increase was driven by the particularly buoyant growth of over 50% on the French market, which now accounts for over 70% of this division’s revenue.

Strong increase in the gross margin, tight control of the operational structure

In the 1^st half of 2016, the gross margin came to 52.5% of revenue, a substantial improvement of 18.2 percentage points. This is a direct result of the increase of Jazz sales in the United States, the market with favorable unit sale prices and an excellent overall product and geographic mix.

The €302 thousand increase in operating expenses compared with the 1^st half of 2015 was mainly due to the €323 thousand increase in sales and marketing costs that accompanied the buoyant growth in activity, in particular in the United States (including €184 thousand in personnel costs following the strengthening of the sales team and the appointment of Brian T. Ennis to head the US subsidiary, as well as a €173 thousand in sales commissions paid to sales agents).

Other operating costs remained stable compared with the 1^st half of 2015, reflecting tight control over expenses.

Taking all these factors into account, Implanet recorded a 17% improvement in its operating result to -€3,556 thousand in the 1^st half of 2016 (vs. -€4,275 thousand in H1 2015) and a 12% improvement in its net loss to -€3,802 thousand (vs. -€4,299 thousand in H1 2015).

Cash, cash equivalents and financial investments

As of June 30, 2016, Implanet had cash and cash equivalents of €2.0 million and financial investments of €1.9 million, i.e. a total of €3.9 million. Operating cash burn was €3.5 million in the first half of 2016, versus €4.6 million in the first half of 2015 (giving a 24% reduction in cash burn).

Implanet also has the possibility to request, under certain conditions, the subscription of 340 convertible bonds coupled with equity warrants (OCABSA) with L1 EUROPEAN HEALTHCARE OPPORTUNITIES FUND for a total amount of €3.4 million, and recently obtained an interest-free innovation loan of €0.8 million from Bpifrance Aquitaine.

Ludovic Lastennet, CEO of Implanet, says: “Over the first half of this year, we have successfully continued to implement our growth strategy in our direct markets: France and the United States. This strategy prioritizes the following development routes: continue our expansion via the contribution of the new Jazz Claw implant for major deformities and Jazz Lock implant for degenerative bone disorders, demonstrate Jazz’s clinical efficacy through major clinical studies and continue improving our financial performance through the ramping up in the United States and tight control over our spending.”

September 22, 2016

German 3D printed orthopedic device manufacturer Emerging Implant Technologies (EIT) has just announced that it has received a significant investment from German private equity company SHS mbH. With the new funds, EIT, a pioneer in making 3D printed medical orthopedic devices, will seek to both expand its international presence, notably within the United States, and continue developing its range of innovative products.

Emerging Implant Technologies was founded in 2014 in Tuttlingen, Germany and has established itself as a reliable manufacturer of 3D printed orthopedic medical devices and implants. Using Selective Laser Melting (SLM) technologies, the young company has developed its own EIT Cellular Titanium(R) structures, which have properties such as 80% porosity and diamond pores the size of roughly 650 μm, which in mimicking trabecular bone structure, help to promote natural bone growth.

The company also offers patient specific implants, and a complete spinal fusion cage portfolio, including a Cervical Cage implant, PLIF cage, TLIF cage, and a soon to be released ALIF cage. Guntmar Eisen, founder and CEO of EIT, explains: “Our EIT Cellular Titanium implants provide the answer to current challenges in implant design and choice of materials as well the extreme cost pressure in medical technology. The additive manufacturing technology allows us to tackle existing problems with new solutions. Thus we can improve the benefits for patients without increasing costs, which is a clear competitive advantage.”

EIT’s new investment, which comes from SHS’s fourth fund generation (itself worth a total of 125 million euro), will facilitate the expansion of the 3D printed medical device manufacturer into other countries such as the United States and will allow them to develop more innovative and useful additively manufactured implants for the medical industry.

As Dr. Bernhard Schirmers, Managing Partner at SHS Gesellschaftfür Beteiligungsmanagement, explains, “EIT’s 3D-printed spine implants have already proven their superior functionality many times in practical applications, thus promoting EIT’s growth. EIT Emerging Implant Technologies’ management team is experienced and successful in the field of spine surgery. As a medical technology investor, we look forward to supporting them on their path to increased growth.”

SHS, which invests primarily in medical technology and life-science companies, is planning on making more investments and even acquisitions within the industry in the coming months. According to a press release, these additional investments will be for companies in Germany, Austria, and Switzerland. SHS’s investments are usually focused on “expansion financing, changes in shareholder structures, and successor situations.”

Posted in 3D Printer Company

ROSEMONT, Ill. and WARSAW, Ind., Sept. 22, 2016 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today pledged to donate up to $100,000 in matching funds to the Orthopaedic Research and Education Foundation (OREF).  According to the agreement, Zimmer Biomet will help underwrite OREF’s grant administration costs by donating 10 cents for every dollar given to OREF by individual donors.

Since 2010, Zimmer Biomet has donated more than $6 million toward advancing OREF’s mission by funding programs, awards and grants including OREF’s Career Development Award, Clinician Development Program, Young Investigator Grants, New Investigator Grants, Resident Research Symposia and Collaborative Research Agenda in Hip/Knee and Trauma.

“Zimmer Biomet and the Orthopaedic Research and Education Foundation share a commitment to advancing the treatment of musculoskeletal disorders and injuries, and we’re pleased this funding will help to defray administration costs and enable the Foundation to invest more financial resources toward its research grants,” said David C. Dvorak, President and CEO of Zimmer Biomet.

The partnership between Zimmer Biomet and OREF will increase the dollars that are available to orthopaedic investigators through OREF’s grant programs and will encourage other donors to support OREF’s mission. Richard F. Santore, MD, OREF Trustee and Chair of the Individual Development Committee, stated, “this support from Zimmer Biomet for peer reviewed research sends an incredibly positive message to current and prospective OREF donors about the value of the work OREF is doing. It allows OREF to keep administrative overhead for grants extremely low.”

According to the U.S. Bone and Joint Initiative, musculoskeletal disorders are the most common causes of long-term pain and disability worldwide, and account for half of all chronic conditions in the elderly. “OREF and Zimmer Biomet share a long history of supporting the best orthopaedic research. This exciting new chapter in our relationship demonstrates Zimmer Biomet’s ongoing commitment to both OREF and the orthopaedic community,” said David G. Lewallen, MD, President of the OREF Board of Trustees.

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

About the Orthopaedic Research and Education Foundation
The Orthopaedic Research and Education Foundation is a charitable 501(c)(3) organization committed to improving lives by supporting excellence in orthopaedic research. OREF is dedicated to supporting new investigators and is the premiere orthopaedic organization funding research across all specialties. A list of research and funding priorities is available at oref.org/grants or follow @oreftoday on Twitter.

Logo – http://photos.prnewswire.com/prnh/20150624/225371LOGO

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

COLUMBIA, Md., Sept. 16, 2016 (GLOBE NEWSWIRE) — Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) provided today an update concerning the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”).

As previously disclosed, the Company is working diligently to complete its previously announced restatements of prior period financial statements and transition to a new independent registered public accounting firm for the 2015 audit so that it is in a position to bring its SEC filings up to date.

The Audit Committee of the Board of Directors has completed an independent review of the accounting matters with the assistance of outside professionals.   The Company, under the direction of the Audit Committee, is working diligently with its former independent registered accounting firm to complete the restatement of its 2014 audited and interim financial statements as soon as possible.   Once that process is complete, the Company expects to transition to a new independent registered accounting firm and begin work on the 2015 financial statements.

As a result of these matters, the Company has delayed the filing of its Annual Report on Form 10-K for the year ended December 31, 2015 (“2015 Form 10-K”), its Quarterly Report on Form 10-Q for the quarter endedMarch 31, 2016 (“Q1 2016 Form 10-Q”), and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016 (“Q2 2016 Form 10-Q”).  As a result, the Company is currently out of compliance with NASDAQ Stock Market Listing Rule 5250(c)(1).

As previously disclosed, the Company submitted to the NASDAQ listing qualifications staff (the “Staff”) a plan to regain compliance with NASDAQ’s continued listing requirements.  On May 24, 2016, NASDAQ granted an exemption to the NASDAQ Listing Rule, extending the deadline until September 12, 2016 for the Company to file all delinquent reports with the SEC, including the 2015 Form 10-K, Q1 2016 Form 10-Q, and Q2 2016 Form 10-Q.  Although the Company is working diligently to finalize these reports, the Company was unable to bring its SEC filings up to date by the September 12, 2016 deadline.

Consequently, on September 14, 2016, the Company received an anticipated letter from NASDAQ, stating that unless the Company requests a hearing before a NASDAQ Listing Qualifications Panel (a “Hearings Panel”) bySeptember 21, 2016, the Company’s common stock will be delisted. Under NASDAQ’s rules and procedures, in general, a company’s request for such a hearing automatically stays any delisting for 15 calendar days from the deadline to request a hearing.  The Company will file a hearing request on or prior to September 21, 2016 and request a further stay. The letter states that the hearing would be expected to occur 30-45 days from the date of the hearing request.

If the Hearings Panel grants the Company’s request for a further stay (which is discretionary on the part of the Hearings Panel and therefore not assured), any final delisting will be stayed until further Hearings Panelproceedings.  The NASDAQ Rules also permit the Company to appeal decisions from the Hearings Department to the NASDAQ Listing Council.

While the Company is continuing to work diligently to complete its previously announced restatements of prior period financial statements and bring its SEC filings up to date, there can be no assurance regarding the timing or ultimate outcome of this process or the ability of the Company to successfully maintain its NASDAQ listing.

The Company is making this announcement in compliance with NASDAQ Listing Rule 5810(b), which requires prompt disclosure of receipt of a noncompliance letter.

About Osiris Therapeutics

Osiris Therapeutics, Inc., based in Columbia, Maryland, is a world leader in researching, developing and marketing regenerative medicine products that improve health and lives of patients and lower overall healthcare costs. Having developed the world’s first approved stem cell drug, the company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine – including bioengineering, stem cell research and viable tissue based products.  Osiris has achieved commercial success with products in orthopaedics, sports medicine and wound care, including BIO^4®, Cartiform^®, Grafix^®, TruSkin ™ and Stravix™.

Osiris, Grafix, and Cartiform are registered trademarks of Osiris Therapeutics, Inc.; TruSkin and Stravix are trademarks of Osiris Therapeutics, Inc.  BIO^4® is a trademark of Howmedica Osteonics Corp. More information can be found on the company’s website, www.Osiris.com. (OSIR-G).

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements about our expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “ongoing,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Examples of forward-looking statements may include, without limitation, statements regarding any of the following: the outcome of the NASDAQ listing qualification deficiency process, including the ability of the Company to successfully maintain its NASDAQ listing; the outcome of the restatements, including the materiality, significance, nature, subject matter, timing or quantitative effects of the Company’s restated financial statements; the timing of the transition to a new independent registered public accounting firm; the completion of the audit of the Company’s 2015 financial statements; and the timing of the filing of the Company’s 2015 Form 10-K, Q1 2016 Form 10-Q and Q2 2016 Form 10-Q. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Our actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the section entitled “Risk Factors” in our Annual Report on Form 10-K and other Periodic Reports filed on Form 10-Q, with the SEC. Accordingly, you should not unduly rely on these forward-looking statements. We undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

For additional information, please contact:

Diane Savoie

Osiris Therapeutics, Inc.

(443) 545-1834

OsirisPR@Osiris.com

Source: Osiris Therapeutics, Inc.